InMode Ltd. (NASDAQ:INMD – Get Free Report) has received an average rating of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $18.54.
INMD has been the topic of a number of analyst reports. UBS Group dropped their target price on InMode from $19.00 to $16.25 and set a “neutral” rating on the stock in a research report on Tuesday, April 29th. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Monday, April 28th. Robert W. Baird lowered InMode from an “outperform” rating to a “neutral” rating and cut their target price for the company from $22.00 to $16.00 in a research report on Monday, April 28th. Baird R W cut InMode from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. Finally, Barclays decreased their price target on shares of InMode from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Wednesday, April 30th.
Get Our Latest Analysis on InMode
Institutional Inflows and Outflows
InMode Stock Down 0.2%
Shares of NASDAQ:INMD opened at $13.34 on Tuesday. The company has a market capitalization of $843.22 million, a price-to-earnings ratio of 5.73 and a beta of 1.98. The company has a 50 day moving average of $14.54 and a two-hundred day moving average of $16.60. InMode has a 52-week low of $13.16 and a 52-week high of $19.85.
InMode (NASDAQ:INMD – Get Free Report) last announced its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a net margin of 44.79% and a return on equity of 17.17%. The firm had revenue of $77.87 million during the quarter, compared to analysts’ expectations of $82.21 million. During the same quarter last year, the company posted $0.32 earnings per share. InMode’s revenue for the quarter was down 3.0% compared to the same quarter last year. On average, equities analysts anticipate that InMode will post 1.75 earnings per share for the current year.
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Stories
- Five stocks we like better than InMode
- Airline Stocks – Top Airline Stocks to Buy Now
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- How to invest in marijuana stocks in 7 steps
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- Insider Trading – What You Need to Know
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.